FDA Approves Dronabinol Oral Solution for Schedule II Placement

Summary

The U.S. Food and Drug Administration (FDA) approved Syndros, a dronabinol oral solution, on July 1, 2016, leading to a DEA scheduling recommendation that placed the product in Schedule II of the Controlled Substances Act (CSA). The DEA is now issuing an interim final rule to officially place FDA-approved oral solutions containing dronabinol in Schedule II of the CSA.